The role of prothrombin complex concentrates in reversal of target specific anticoagulants

Thrombosis Journal

Volumn 12, Issue 1, 2014, Pages

  Babilonia, Katrina ^a   Trujillo, Toby ^b  

^a UNIVERSITY OF COLORADO HOSPITAL   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; PROTHROMBIN COMPLEX; RIVAROXABAN;

ANTICOAGULATION; BLEEDING TIME; BLOOD CLOTTING; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; BLOOD LEVEL; BLOOD SAMPLING; CREATININE CLEARANCE; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HUMAN; KIDNEY FUNCTION; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; REVIEW; THROMBIN TIME;

EID: 84899974093     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/1477-9560-12-8     Document Type: Review

References (47)

1. Patel MR, Mahaffey KW, Garg J, Pan G, Singer D, Hacke W, Breithardt G, Halperin J, Hankey G, Piccini J, Becker R, Nessel C, Paolini J, Berkowitz S, Fox K, Califf R. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-891. 10.1056/NEJMoa1009638, 21830957.
2. Connolly SJ, Ezekowitz MD, Yusuf S, Eilelboom J, Oldgren J, Parekh A, Pogue J, Reilly P, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis B, Darius H, Kiener HC, Joyner C, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151. 10.1056/NEJMoa0905561, 19717844.
3. Granger CB, Alexander JH, McMurray JJ, Lopes R, Hylek E, Hanna M, Al-Khalidi A, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton D, Ezekowitz J, Flaker G, Garcia D, Geraldes M, Gersh B, Golitsyn S, Goto S, Hermosillo A, Hohnloser S, Horowoitz J, Mohan P, Jansky P, Lewis B, Sopez-Sendon J, Pais P, Parkhomenko A, Verheugt F, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365:981-992. 10.1056/NEJMoa1107039, 21870978.
4. Investigators E, Bauersachs R, Berkowitz SD, Brenner B, Buller H, Decousus H, Gallus A, Lensing A, Misselwitz F, Prins M, RAshkob G, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson B, Piovella F, Schellong S. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010, 363:2499-2510.
5. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt D, Goodman S, Verheugt F, Flather M, Huber K, Liaw D, Husted S, Lopez-Sendon J, Caterina R, Jansky P, Darius H, Vinereaniu D, Cornel J, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzylio W, Diaz R, White H, Ruda M, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011, 365:699-708. 10.1056/NEJMoa1105819, 21780946.
6. Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas S, Merli G, Knabb R, Weitz J, ADOPT Trial Investigators Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 2011, 365:2167-2177. 10.1056/NEJMoa1110899, 22077144, ADOPT Trial Investigators.
7. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt D, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox K, Goto S, Murphy S, Plotnikov A, Schneider D, Sun X, Verheigt F, Gobson M, ATLAS ACS 2-Timi 51 Investigators Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012, 366:9-19. 10.1056/NEJMoa1112277, 22077192, ATLAS ACS 2-Timi 51 Investigators.
8. Weitz JI, Eikelboom JW, Samama MM, American College of Chest P New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines. Chest 2012, 141:e120S-e151S. 3278067, 22315258, American College of Chest P.
9. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008, 36:386-399. 10.1124/dmd.107.019083, 18006647.
10. Liesenfeld KH, Schafer HG, Troconiz IF, Tillmann C, Eriksson BI, Stangier J. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol 2006, 62:527-537. 10.1111/j.1365-2125.2006.02667.x, 1885168, 17061960.
11. Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010, 49:259-268. 10.2165/11318170-000000000-00000, 20214409.
12. Kubitza D, Becka M, Mueck W, Halabi A, Maatouk H, Kause N, Lufft V, Wand DD, Philipp T, Bruck H. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 2010, 70:703-712. 10.1111/j.1365-2125.2010.03753.x, 2997310, 21039764.
13. Nutescu E. Apixaban: a novel oral inhibitor of factor Xa. Am J Health-Syst Pharm 2012, 69:1113-1126. Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010; 104:1263-1271.
14. Baglin T. The role of the laboratory in the treatment with new oral anticoauglants. J Thromb Haemost 2013, 11(Suppl. 1):122-128.
15. Mani H, Kasper A, Lindhoff-Last E. Measuring the anticoagulant effects of target specific oral anticoagulants-reasons, methods and current limitations. J Thromb Thrombolysis 2013, 36:187-194. 10.1007/s11239-013-0907-y, 23512159.
16. Kalus J. Pharmacologic interventions for reversing the effects of oral anticoagulants. AJHP 2013, 70(suppl 1):S12-S21.
17. FEIBA NF. (Anti-inhibitor Coagulant Complex, Nanofiltered and Vapor Heater) Prescribing Information 2011, Wetlake Village, CA: Baxter Heathcare Corporation, Feb. http://www.baxter.com/downloads/healthcare_professionals/products/feiba-nf-pi.pdf.
18. Nitzki-George D, Wozniak I, Caprini J. Current state of knowledge on oral anticoagulant reversal using procoagulant factors. Ann Pharmacother 2013, 47:841-855. 10.1345/aph.1R724, 23695644.
19. Sorensen B, Spahn D. Clinical review: Prothrombin complex concentrates - evaluation of safety and thrombogenicity. Crit Care 2011, 15:201-210. 10.1186/cc9311, 3222012, 21345266.
20. Song MM, Warne CP, Crowther MA. Prothrombin complex concentrate (PCC, Octaplex) in patients requiring immediate reversal of vitamin K antagonists anticoagulation. Thromb Res 2012, 129:526-529. 10.1016/j.thromres.2011.12.007, 22304928.
21. Lubetsky A, Hoffman R, Zimlichman R, Eldor A, Zvi J, Kostenko V, Brenner B. Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulation. Thromb Res 2004, 113:371-387. 10.1016/j.thromres.2004.04.004, 15226091.
22. Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H. Prothrombin complex concentrate (Beriplax P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost 2008, 6:622-631. 10.1111/j.1538-7836.2008.02904.x, 18208533.
23. Preston FE, Laidlaw ST, Sampson B, Kitchen S. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safey in 42 patients. Br J Haematol 2002, 116:619-624. 10.1046/j.0007-1048.2001.03295.x, 11849221.
24. Holbrook A, Schulman S, Will DM, Vandvik PO, Fish J, Kovacs PO, Svensson P, Veenstra D, Crowther M, Guyatt G. Evidence- based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012, 141(s2):e152S-e184S. 3278055, 22315259.
25. Arnekian V, Camous J, Fattal S, Rezaiguia-Delclaux S, Nottin R, Stephan F. Use of prothrombin complex concentrate for excessinve bleeding after cardiac surgery. Interact Cardiovasc Thorac Surg 2012, 15:382-389. 10.1093/icvts/ivs224, 3422937, 22623627.
26. Davenport R, Khan S. Management of major trauma haemorrhage: treatment priorities and controversies. Br J Haematol 2011, 155:537-548. 10.1111/j.1365-2141.2011.08885.x, 22017416.
27. Kaatz S, Crowther M. Reversal of target-specific oral anticoagulants. J Thromb Thrombolysis 2013, 36(2):195-202. 10.1007/s11239-013-0923-y, 23657589.
28. Sorensen B, Spahn D, Innerhofer P, Spannagl M, Rossaint R. Clinical review: Prothrombin complex concentrates - evaluation of safety and thrombogenicity. Crit Care 2011, 15:201-210. 10.1186/cc9311, 3222012, 21345266.
29. Product Information KCENTRA Intravenous Powder, Prothrombin Complex Concentrate (Human) Intravenous Powder 2013, Kankakee, IL: CSL Behring LLC (per manufacturer), Product Information.
30. Van Ryn J, Schurer J, Kink-Eiband M, Clemens A. The successful reversal of dabigatran- induced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with ex vivo markers of anticoagulation. Blood 2011, 118(21):1004.
31. Van Ryn J, Ruehl D, Priepke H, Hauel N, Wienen W. Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate. Haematologica 2008, 93(s-1):148.
32. Pragst I, Zeitler SH, Doerr B, Kaspereit JF, Herzog E, Dickneite G, van Ryn J. Reversal of dabiagatran anticoagulation by prothrombin complex concentrate (Beroplex P/N) in a rabbit model. J Thromb Haemost 2012, 10(9):1841-1848. 10.1111/j.1538-7836.2012.04859.x, 22812619.
33. Marlu R, Hoadaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomized crossover ex-vivo study in healthy volunteers. Thromb Haemost 2012, 108:217-247. 10.1160/TH12-03-0179, 22627883.
34. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011, 124:1573-1579. 10.1161/CIRCULATIONAHA.111.029017, 21900088.
35. Lillo-Le Louet A, Wolf M, Soufir L, Galbois A, Dumenil AS, Offenstadt G, Samama MM. Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation. Thromb Haemost 2012, 108:583-585. 10.1160/TH12-03-0149, 22782645.
36. Dager WE, Gosselin RC, Roberts AJ. Reversing dabigatran in a life-threatening bleed occurring during cardiac ablation with factor eight inhibitor bypassing activity. Cri Care Med 2013, 41(5):42-46.
37. Godier A, Miclot A, Le Bonniec B, Durand M, Fischer AM, Emmerich J, Marchand-Leroux C, Lecompte T, Samama CM. Evaluation of the prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesia 2012, 116:94-102.
38. Perzborn E, Gruber A, Tinel H, Marzec U, Buetehorn U, Buchmueller A, Heitmeier S, Laux V. Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Throm and Haem 2013, 110(1):162-172.
39. Martin A, Bonniec B, Fischer A, Marchand-Laroux C, Gaussem P, Samama CM, Godier A. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis. J Int Card 2013, http://dx.doi.org/10.1016/j.icard.2013.07.152.
40. Product Information PRADEXA® Oral Tablets, Dabigatran Oral Tablets 2011, Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals (per manufacturer).
41. Product Information XARELTO(R) Oral Tablets, Rivaroxaban Oral Tablets 2012, Titusville, NJ: Janssen Pharmaceuticals, Inc. (per manufacturer), Product Information.
42. Product Information ELIQUIS(R) Oral Tablets, Apixaban Oral Tablets 2012, Princeton, NJ: Bristol-Myers Squibb (per manufacturer), Product Information.
43. Van Ryn J, Litzenburger T, Waterman A, Canada K, Hauel N, Sarko C, Kroe-Barrett R, Singh S, Park J. Dabigatran anticoagulant activity is neutralized by an antibody selective to dabigatran in in vitro and in vivo models. J Am Coll Cardiol 2011, 57(14):E 1130.
44. Mirayes M, Davis K. Neweroral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient. AJHP 2012, 69:1473-1484.
45. Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P, Hutchaleelaha A, Inagaki M, Conley PB, Phillips DR, Sinha U. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013, 19(4):446-451. 10.1038/nm.3102, 23455714.
46. Hillarp A, Baghaei F, Fagerberg Blixter I, Gustafsson M, Stigendal L, Sten-Linder M, Strandberg K, Lindahl TL. Effects of the oral, direct factor Xa inhibitor rvaroxaban on commonly used coagulation assays. J Throm Haem 2010, 9:133-139.
47. Van Ryn J, Stangier J, Haertter S, Heinz Lisenfeld K, Wienen W, Feuring M, Clemens A. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Throm Haem 2010, 6:1116-1127.